HPV as a marker for molecular characterization in head and neck oncology: Looking for a standardization of clinical use and of detection method(s) in clinical practice
Head & Neck2019Vol. 41(4), pp. 1104–1111
Citations Over TimeTop 10% of 2019 papers
Francesco Bussu, Camille Ragin, Paolo Boscolo‐Rizzo, Davide Rizzo, Roberto Gallus, Giovanni Delogu, Patrizia Morbini, Massimo Tommasino
Abstract
In the FFPE samples, the immunohistochemistry of p16, which is considered appropriate to assess HPV-driven carcinogenesis in OPSCC according to the 8th American Joint Committee on Cancer TNM classification, may not be specific enough to become the diagnostic standard in the perspective of treatment deintensification. p16 may play a safer role in combination with another highly sensible assay. Other promising approaches are based on DNA detection through real-time polymerase chain reaction and RNAscope.
Related Papers
- → Partial verification bias and incorporation bias affected accuracy estimates of diagnostic studies for biomarkers that were part of an existing composite gold standard(2016)20 cited
- → Comparison of microscopy and radiography as gold standards in radiographic caries diagnosis(1999)28 cited
- → ‘Cure’ as the gold standard for likelihood ratio assessment: theoretical considerations(2004)18 cited
- ['Gold standard', not 'golden standard'].(2005)
- → Reply to: Validity of ultrasound in predicting acute appendicitis among children, keeping histopathology as gold standard: Methodological issues(2019)